Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29319351 | 0.88 | LMNA (0.44) | LMNAMEN1KMT2AHTTALDH1A1 | |
| SCHEMBL29319306 | 0.86 | LMNA (0.45) | LMNAMEN1KMT2AHTTALDH1A1 | |
| SCHEMBL29319311 | 0.86 | LMNA (0.45) | LMNAMEN1KMT2AHTTALDH1A1 | |
| SCHEMBL29319341 | 0.85 | LMNA (0.44) | LMNAMEN1KMT2AHTTALDH1A1 | |
| SCHEMBL29319346 | 0.84 | LMNA (0.43) | LMNAMEN1KMT2AHTTALDH1A1 | |
| SCHEMBL29319143 | 0.84 | MEN1 (0.49) | LMNAMEN1KMT2AHTTALDH1A1 | |
| SCHEMBL24273884 | 0.84 | MEN1 (0.46) | LMNAMEN1KMT2AHTTALDH1A1 | |
| SCHEMBL29319220 | 0.83 | MEN1 (0.48) | LMNAMEN1KMT2AHTTALDH1A1 | |
| SCHEMBL29329749 | 0.82 | LMNA (0.42) | LMNAMEN1KMT2AHTTALDH1A1 | |
| SCHEMBL2252835 | 0.78 | LMNA (0.66) | LMNAMEN1KMT2AALDH1A1HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238265-A1 | ADAMANTANE AMIDES AND THIOAMIDES FOR THE TREATMENT OF EBOLAVIRUS INFECTION | ARISAN THERAPEUTICS INC. (US) | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238265-A1 | ADAMANTANE AMIDES AND THIOAMIDES FOR THE TREATMENT OF EBOLAVIRUS INFECTION | IFNAR1, NR4A3, NR0B2 | LMNA 3555/4885MEN1 3448/4885KMT2A 1728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.